U.S. Dna Diagnostics Market Size & Outlook, 2023-2030

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dna diagnostics market will help companies and investors design strategic landscapes.

Pcr-based diagnostics was the largest segment with a revenue share of 49.93% in 2023. Horizon Databook has segmented the U.S. dna diagnostics market based on pcr-based diagnostics, ngs dna diagnosis, in-situ hybridization diagnostics, microarrays-based diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.

The U.S. is expected to be the largest market for DNA diagnostics in North America due to the high cancer prevalence in the country and consequent rapid adoption of diagnostic tests. Some other factors propelling market growth in the country include the increasing prevalence of genetic disorders and the growing emphasis on personalized medicine. As healthcare shifts toward tailored treatments, genetic testing plays a critical role in identifying the right therapies for patients.

In addition, significant technological advancements, an increasing number of FDA approvals for tests, and competition among biotechnology companies are projected to boost the market over the forecast period. Moreover, according to an article published by the National Library of Medicine in April 2023, over the past two decades, genetic testing has grown in popularity around the world. The U.S. established the Genetic Testing Registry (GTR) in response to the swift advancement of genetic tests, with the aim of facilitating public access to data regarding genetic tests and the associated labs. Researchers examined changes in the accessibility of genetic tests in the U.S. over the past 10 years using data from the GTR that is made available to the public.

As of November 2022, around 129,624 genetic tests performed in the U.S., including upgraded versions of previously existing tests, had been made publicly accessible & reported to the genetic testing registry. In contrast to research, over 90% of the tests that are submitted to GTR are for clinical use. Hence, a growing number of diagnostic examinations is expected to boost the market over the forecast period.